BioMerieux snares stake in Knome

France's BioMerieux has acquired a 10 percent stake in Knome for $5 million and struck a deal to use the Cambridge, MA-based company's genome sequencing and analysis services. "The deal with Knome allows the group to strengthen its position in molecular biology and to create diagnostic tools for tomorrow," CM-CIC Securities analyst Arsene Guekam said in a research note. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.